Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rakesh Kumar Raman
Observed names:
R.K. Raman,
Rakesh K. Raman,
Rakesh Raman
Institutions:
National Council Of Educational Research And Training,
National Dairy Research Institute
Observed institutions:
National Council Of Educational Research And Training,
Pondicherry University,
National Dairy Research Institute,
Revolution Medicines (United States),
AstraZeneca (United States),
Acerta Pharma BV (Netherlands)
show all 6
ORCID:
0000-0003-2229-6642
Observed ORCID:
0000-0003-2229-6642
OpenAlex ID:
A5047195069
Review on factors affecting and control of post-acidification in yoghurt and related products
2021
·
Gaurav Kr Deshwal
, Swati Tiwari
, et al.
·
Trends in Food Science & Technology
·
226
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
2021
·
Kerry A. Rogers
, Philip A. Thompson
, et al.
·
Haematologica
·
116
PDF
Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies
2021
·
Helena Edlund
, Núria Buil‐Bruna
, et al.
·
British Journal of Clinical Pharmacology
·
15
PDF
Flaxseed (Linum usitatissimum)
2020
·
Sangita Ganguly
, Narender Raju Panjagari
, et al.
·
Springer eBooks
·
15
Abstract PR010: Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-001
2023
·
Alexander I Spira
, Alexander N Starodub
, et al.
·
Molecular Cancer Therapeutics
·
14
Phase 2 Study of Acalabrutinib in Ibrutinib‐intolerant Patients With Relapsed/refractory Chronic Lymphocytic Leukemia
2019
·
K.A. Rogers
, P.A. Thompson
, et al.
·
Hematological Oncology
·
9
PDF
Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
2019
·
Kerry Anne Rogers
, Philip A. Thompson
, et al.
·
Journal of Clinical Oncology
·
9
Phytochemical properties of spray dried jamun juice powder as affected by encapsulating agents
2020
·
Rakesh Kumar Raman
, Swaminathan Santhalakshmy
, et al.
·
Journal of Pharmacognosy and Phytochemistry
·
7
Characterisation of pure goat and admixed goat-buffalo milk khoa: Physico-chemical, texture, microstructure and storage stability
2024
·
FNU Akshit
, Gaurav Kr Deshwal
, et al.
·
Food and Humanity
·
3
Effect of encapsulating agents on antioxidative properties of spray dried jamun juice powder
2020
·
Rakesh Kumar Raman
, Swaminathan Santhalakshmy
, et al.
·
International Journal of Chemical Studies
·
2
Bikaneri Camel Milk-Derived Low-Molecular-Weight Peptides as a Novel Therapeutic Approach for Diabetes
2026
·
Sunny Kalyan
, Rakesh Kumar Raman
, et al.
·
International Journal of Peptide Research and Therapeutics
·
1
Impact of Low-Molecular-Weight (<3 kDa) Camel Milk Casein and Whey Protein Hydrolysates on Hyperglycemia and Associated Hyperlipidemia, Oxidative Stress, and Reproductive Health in Type 2 Diabetic Male Rats
2025
·
Sunny Kalyan
, Rakesh Kumar Raman
, et al.
·
ACS Food Science & Technology
·
1
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
2019
·
Kerry A. Rogers
, Philip A. Thompson
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
Hypocholesterolemic and Antioxidative Effects of Whole and Skimmed Goat Milk in Cholesterol-Fed Wistar Albino Rats
2026
·
Sunny Kalyan
, Rakesh Kumar Raman
, et al.
·
International Journal of Advanced Biochemistry Research
Headspace volatile markers of Sandesh, a chhana-based delicacy stored at elevated temperatures
2024
·
Karpurapu Uma
, Narender Raju Panjagari
, et al.
·
Indian Journal of Dairy Science
Abstract 3023: Exposure versus efficacy/safety of acalabrutinib and its pharmacologically active metabolite, ACP-5862, for the treatment of chronic lymphocytic leukemia
2020
·
Helena Edlund
, Karthick Vishwanathan
, et al.
·
Cancer Research
Ps1151 Phase 2 Study of Acalabrutinib in Ibrutinib‐intolerant Patients With Relapsed/refractory Chronic Lymphocytic Leukemia
2019
·
K. Rogers
, P.A. Thompson
, et al.
·
HemaSphere
Show more works
View as search
Works count:
17
Citation count:
419
H-index:
7
I10-index:
5
Year
Topic
Type